Join Now - it is FREE

Basic level includes our interactive biotech chatroom, forum, biotech stock screener; you also receive the biotech digest in your email everyday.

==

Make Money Swing Trading - Join My New Trading Group - Email drkkde@gmail.com Now

==
swing trading
==

Synergy Pharmaceuticals Inc. ($SGYP) stock continues its strong upward movement in the new year. The company stock has gained 67% in the past one year while its Year to Date gain stands at over 10%. The stock is buoyant as Synergy has strong catalysts coming its way.
The company is scheduled to have its PDUFA target action date on January 29, 2017. This is the date when the FDA will offer its decision on the company’s NDA for plecanatide in the treatment of chronic idiopathic constipation. The company currently does not have any approved product in its portfolio. Synergy focuses on developing novel gastrointestinal (GI) therapies.

Herbalife ($HLF) stock shows strong movements in its Friday trading sessions. The stock recorded intraday high of $52.20, before closing at $52, up 4.12%. The stock reacted to the news of the resignation by Federal Trade Commission Chairwoman Edith Ramirez. She had been a vocal opponent of the company’s marketing practices. The investors have viewed the resignation as a positive news for the company.
Herbalife has been under FTC radar for quite some time. Last year, the company was made to agree to a $200 million settlement with the FTC for compensating its distributors. Herbalife was also ordered by the commission to change its policy to payment on actual sales basis.

 

• Nivalis Therapeutics ($NVLS) announced a restructuring plan which includes reducing its headcount by 83%. It will also lay off its CEO and CMO.
• RXi Pharmaceuticals ($RXII) disclosed in a filing that OPKO Health ($OPK) owns 5% stake in the firm.

• The FDA has extended its PDUFA action date by three months for reviewing Eli Lilly's ($LLY) New Drug Application seeking approval of baricitinib for the treatment of moderate-to-severe rheumatoid arthritis.
• Biogen ($BIIB) announced that the Phase 3 ENDEAR study assessing SPINRAZA (nusinersen) in infants with spinal muscular atrophy (SMA) met its primary endpoint.

• Acasti Pharma ($ACST) announced its third quarter loss at C$0.22 per share. It closed the quarter with cash and equivalents of C$5.8 million.
• Neptune Technologies ($NEPT) reported its third quarter operating loss at C$0.5 million. It reported 119.9% year over year increase in its revenue to C$12.14 million.

• Axovant Sciences ($AXON) received a Buy rating from Oppenheimer. The price target for the stock has been set at $20 apiece.
• Novavax ($NVAX) received a Buy rating from Cantor Fitzgerald. The price target for the stock has been set at $2 apiece.

Gainers (% price change) Last Trade Change Mkt Cap
DexCom, Inc.
DXCM (NASDAQ)
85.13 +17.52 (25.91%) 7.05B
Sangamo Therapeutics Inc
SGMO (NASDAQ)
4.40 +0.45 (11.39%) 336.29M
Array Biopharma Inc
ARRY (NASDAQ)
10.87 +0.76 (7.52%) 1.97B
Amicus Therapeutics, Inc.
FOLD (NASDAQ)
5.95 +0.36 (6.44%) 843.82M
Cardiovascular Systems
CSII (NASDAQ)
26.42 +1.53 (6.13%) 896.42M
Losers (% price change)
Zogenix, Inc.
ZGNX (NASDAQ)
10.35 -1.15 (-10.00%) 249.01M
Antares Pharma Inc
ATRS (NASDAQ)
2.09 -0.11 (-5.00%) 312.76M
Kindred Healthcare, Inc.
KND (NYSE)
7.65 -0.20 (-2.55%) 651.48M
Rockwell Medical Inc
RMTI (NASDAQ)
6.07 -0.15 (-2.41%) 303.50M
Valeant Pharmaceuticals
VRX (NYSE)
15.33 -0.30 (-1.92%) 5.33B
Most Actives (dollar volume)
DexCom, Inc.
DXCM (NASDAQ)
85.13 +17.52 (25.91%) 7.05B
Pfizer Inc.
PFE (NYSE)
32.52 -0.08 (-0.25%) 195.96B
Merck & Co., Inc.
MRK (NYSE)
62.34 +0.13 (0.21%) 173.50B
Gilead Sciences, Inc.
GILD (NASDAQ)
73.07 -0.29 (-0.40%) 95.73B
Johnson & Johnson
JNJ (NYSE)
114.60 -0.02 (-0.02%) 311.47B